Table 2—

Patients characteristics#

Patients registered
 Assessable for response intention to treat170 (100)
 Assessable for survival164 (96.5)
 Assessable for toxicity170 (100)
Age
 Median 61 yrs
 <60 yrs66 (40.3)
 ≥60 yrs98 (59.7)
Sex
 Male128 (78.0)
 Female36 (22.0)
ECOG performance status
 0 Karnofsky 100%34 (20.7)
 1 Karnofsky 80–90%92 (56.1)
 2 Karnofsky 60–70%37 (22.6)
Extent of disease
 Limited disease4 (2.4)
 Extensive disease without distant metastasis38 (23.2)
 Extensive disease with distant metastasis120 (73.2)
 No data2 (1.2)
Liver metastases
 Present59 (36.0)
 Absent105 (64.0)
Brain metastases
 Present46 (28)
 Absent118 (72)
Best response to first-line treatment
 Complete response31 (18.9)
 Partial response95 (57.9)
 Stable disease9 (5.5)
 Progression29 (17.7)
Time to relapse after first-line therapy
 <3 months refractory57 (34.8)
 ≥3–<6 months sensitive107 (65.2)
Time to progression after first-line therapy
 Median days191
Prior anticancer treatment
 Prior radiotherapy85 (51.8)
 Prior surgery17 (10.4)
First-line therapy
 Platinum-based104 (63.4)
 Nonplatinum-based60 (36.6)
First-line chemotherapy regimen
 Carboplatin, etoposide, vincristin48 (29.3)
 Platinum cisplatin or carboplatin, etoposide36 (21.9)
 Carboplatin, taxol, etoposide7 (4.3)
 Adriamycin, cyclophosphamide, vincristine20 (12.2)
 Epirubicin, cyclophosphamide, vincristine20 (12.2)
 Cyclophosphamide, etoposide, adriamycin12 (7.3)
 Other regimes21 (12.4)
Number of measurable lesions
 169 (42.1)
 250 (30.5)
 333 (20.1)
 >312 (7.2)
  • Data are presented as n (%), unless otherwise stated. ECOG: Eastern Cooperative Oncology Group. #: n = 170.